Australia's most trusted
source of pharma news
Thursday, 06 February 2025
Posted April 28 2023 PM
Fresh from a global downsizing, Novartis is swinging the axe again - this time slashing its pipeline by 10 per cent as the company doubles down on its 'pure play' strategy focused on five core areas.
At a quarterly update, CEO Vas Narasimhan told investors the pipeline "clean up" would allow the company to spend more on the most promising areas within its already defined areas of focus.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.